Publications

Search our bibliography using the filters on the right-hand side.

Displaying 151 through 200 of 350 publications.

Huybrechts KF, Brookhart MA, Rothman KJ, Silliman RA, Gerhard T, Crystal S, Schneeweiss S. Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients. Am J Epidemiol. 2011 Nov 1;174(9):1089-99.

Ascher-Svanum H, Novick D, Haro J, Aguado J, Cui Z, Anand H. Empirically-driven definitions of 'good', 'moderate' and 'poor' levels of functioning in the treatment of schizophrenia. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 2011. Madrid, Spain. [abstract] Value Health. 2011 Nov; 14(7):A287. doi: 10.1016/j.jval.2011.08.307

Bell C, McLeod LD, Nelson LM, Fehnel SE, Zografos LJ, Bowers B. Development and psychometric evaluation of a new patient-reported outcome instrument measuring the functional impact of insomnia. Qual Life Res. 2011 Nov 1;20(9):1457-68.

Markowitz M, Karve S, Panish J, Candrilli S, Cosmatos I, Alphs L. Evaluating antipsychotic adherence patterns among Medicaid-enrolled hospital-discharged patients with schizophrenia. Poster presented at the Psychiatric and Mental Health Congress; November 2011.

Coon CD, Nelson LM, Gilligan T. Advanced psychometric methods for PRO development – factor analysis. Presented at the 18th Annual Conference for the International Society for Quality of Life Research; October 2011.

Gili M, Luciano JV, Bauzá N, Aguado J, Serrano MJ, Armengol S, Roca M. Psychometric properties of the IDS-SR30 for the assessment of depressive symptoms in Spanish population. BMC Med Res Methodol. 2011 Sep;21(11):131.

López-León S, Fortuny J, Plana E, Zhu Y, Rivero E. The pattern of use of anti-depressant drugs in a pediatric population in a US managed care population. Poster presented at the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug; 20(Suppl 1):S101.

López-León S, Fortuny J, Plana E, Zhu Y, Rivero E. Adherence to antidepressant treatment among pediatric population in a US managed care population. Poster presented at the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug; 20(Suppl 1):S316.

Gonzalez-Pinto A, Vieta E, Reed C, Novick D, Barraco A, Aguado J, Haro JM. Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania--results of a two year observational study in bipolar disorder (EMBLEM). J Affect Disord. 2011 Jun;131(1-3):320-9.

Karve SJ, Panish J, Dirani R, Candrilli SD. Annual health care costs for patients with schizophrenia experiencing multiple relapses after initiation of a second-generation oral antipsychotic. Poster presented at the 164th Annual Meeting of the American Psychiatric Association; May 2011.

Panish J, Karve S, Candrilli S, Dirani R. Association between adherence and persistence with antipsychotics and outcomes among Medicaid patients with schizophrenia. Poster presented at the 164th Annual Meeting of the American Psychiatric Association; May 2011.

Lançon C, DiBenedetti DB, Lewis SA, Davis KH, Danchenko N, François C. Assessing the impact of major depressive disorder (MDD) on family functioning: development of the depression and family functioning scale. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 2011. Baltimore, MD. [abstract] Value Health. 2011 May; 14(3):A195.

Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. Can Med Assoc J. 2011 Apr 1;183(7):E411-9.

Forns J, Torrent M, Garcia-Esteban R, Caceres A, Gomila MP, Martinez D. 4-year-old neurodevelopment and early life determinants are longitudinally associated to 11-year-old attention function. Poster presented at the 23rd Congress of International Society of Environmental Epidemiology (ISEE); 2011. Barcelona, Spain.

Meyers J, Classi P, Wietecha L, Candrilli S. Economic burden and comorbidities of attention-deficit/hyperactivity disorder among pediatric patients hospitalized in the United States. Child Adolesc Psychiatry Ment Health. 2010 Dec 1;4:31.

Lang K, Meyers JL, Korn JR, Lee S, Sikirica M, Crivera C, Dirani R, Menzin J. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv. 2010 Dec 1;61(12):1239-47.

Arana A, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. Authors reply. N Engl J Med. 2010 Nov 4;363(19):1873-4.

Coon CD, Price MA, Nelson LM. Advanced patient-reported outcomes assessment: psychometric methods. Presented at the 2010 ISPOR 13th Annual European Congress; November 2010. Prague, Czech Republic.

Novick D, Reed C, Haro JM, Gonzalez-Pinto A, Perrin E, Aguado J, Tohen M. Comparison of olanzapine and risperidone in the EMBLEM study: translation of randomized controlled trial findings into clinical practice. Int Clin Psychopharmacol. 2010 Sep;25(5):257-63.

Nagar S, Sherer JT, Chen H, Aparasu RR. Extent of functional impairment in children and adolescents with depression. Curr Med Res Opin. 2010 Sep;26(9):2057-64.

Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med. 2010 Aug 6;363(6):542-51.

Sasane R, Mitra D, Hodgkins P, Davis KL. Childhood ADHD in Europe: a comparison of patient and physician profiles across countries. Poster presented at the 23rd ECNP Congress; August 2010. [abstract] Eur Neuropsychopharmacol. 2010 Aug; 20(Suppl. 3):S616-7.

Mitra D, Sasane R, Hodgkins P, Davis KL. Management of ADHD among children in Europe: a comparison of practice patterns across countries. Poster presented at the 23rd ECNP Congress; August 2010. [abstract] Eur Neuropsychopharmacol. 2010 Aug; 20(Suppl. 3):S625-6.

López-León S, Fortuny J, Plana E, Rivero E. The pattern of use of anti-depressant drugs. Poster presented at the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2010. Brighton, United Kingdom. [abstract] Pharmacoepidemiol Drug Saf. 2010 Aug; 19(1):S289.

Geissbühler Y, Plana E, Tuvblad C. Methylphenidate treatment in children and adolescents with attention deficit/hyperactivity disorder: a drug utilization study in an US database. Poster presented at the International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2010. Brighton, England.

Meyers J, Classi P, Wietecha LA, Candrilli S. The burden of attention-deficit/hyperactivity disorder (ADHD) on patients hospitalized with a primary diagnosis of oppositional defiant disorder (ODD). Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A182.

Classi P, Meyers J, Wietecha L, Candrilli S. Characteristics of hospitalizations for attention-deficit/hyperactivity disorder (adhd) among children and adolescents in the united states from 2000-2006. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May 1; 13(3):A111.

Graham C, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating a cost-effectiveness analysis comparing olanzapine with ziprasidone in the treatment of schizophrenia. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May 1; 13(3):A113.

Luciano JV, Ayuso-Mateos JL, Fernandez A, Aguado J, Serrano-Blanco A, Roca M, Haro JM. Utility of the twelve-item World Health Organization Disability Assessment Schedule II (WHO-DAS II) for discriminating depression "caseness" and severity in Spanish primary care patients. Qual Life Res. 2010 May;19(1):97-101.

Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010 Apr 1;24(4):489-96.

Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.

Zarkin GA, Cowell AJ, Hicks KA, Dunlap LJ, Belenko S, Mills MJ, Houser K, Keyes VS. Benefits and costs of alternative substance abuse treatment programs for individuals in state prisons: results from a lifetime simulation model. Presented at the International Society for the Study of Drug Policy Conference 2010; March 15, 2010. Santa Monica, CA. Previously presented at the Addiction Health Services Research Annual Conference.

Nagar S, Mehta S, Bhatara V, Aparasu R. Health care consequences of black-box warnings for antidepressants in the United States and Canada. Res Social Adm Pharm. 2010 Mar;6(1):78-84.

Goldberg JF, McLeod LD, Fehnel SE, Williams VSL, Hamm LR, Gilchrist K. Development and psychometric evaluation of the Bipolar Functional Status Questionnaire (BFSQ). Bipolar Disord. 2010 Feb 1;12(1):32-44.

Zarkin GA, Cowell AJ, Dunlap LJ, Hicks KA, Keyes VS, Mills MJ, Belenko S, Houser K. The benefits and costs of prison-based substance abuse treatment. Presented at the Federal Consortium Addressing the Substance Abusing Offender; January 2010. Washington, DC.

Williams VS, Morlock RJ, Feltner D. Psychometric evaluation of a visual analog scale for the assessment of anxiety. Health Qual Life Outcomes. 2010 Jan 1;8:57.

Palmsten K, Setoguchi S, Margulis AV, Patrick A, Hernández-Díaz S. Elevated risk of preeclampsia in pregnant women with depression: disease vs. antidepressants. Poster presented at the 2010 International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 2010.

Arana A, Wentworth CE, Arellano FM. Validity of the codes of suicidality in the THIN database. Drug Saf. 2010;19(12):1316-7.

Arana A, Arellano F, Wentworth CE, Price J. An algorithm for the diagnosis of suicide in the THIN database. Presented at the 26th International Conference on Pharmacoepidemiology; 2010.

Rofail D, Kitchen H, Heyes A, Heron L, Sacco P. Cognitive impairment associated with schizophrenia: the humanistic and economic burden. Poster presented at the American Neurological Association; 2010. San Francisco, CA.

Anderson IM, Jones S, Twiss J. Do negative cognitive style and personality predict depression symptoms and functional outcomes in severe bipolar and unipolar disorders? Int J Cogn Ther. 2009 Dec 15;2(4):343-53. doi: 10.1521/ijct.2009.2.4.343

Johannes CB, Clayton AH, Odom DM, Rosen RC, Russo PA, Shifren JL, Monz BU. Distressing sexual problems in United States women revisited: prevalence after accounting for depression. J Clin Psychiatry. 2009 Dec 1;70(12):1698-706.

Zarkin GA, Cowell AJ, Dunlap LJ, Hicks KA, Keyes VS, Mills MJ. Benefits and costs of alternative substance abuse treatment programs for individuals in state prisons: results from a lifetime simulation model. Presented at the American Society of Criminology Annual Meeting; November 2009. Previously presented at the Addiction Health Services Research Annual conference.

Hicks KA, Zarkin GA, Dunlap LJ, Cowell AJ, Mills MJ, Keyes VS. A dynamic model for estimating the costs and benefits on prison-based substance abuse treatment. Poster presented at the American Society of Criminology Annual Meeting; November 2009.

Zarkin GA, Cowell AJ, Hicks KA, Dunlap LJ, Belenko S, Mills MJ. Benefits and costs of alternative substance abuse treatment programs for individuals in state prisons: results from a lifetime simulation model. Presented at the Addiction Health Services Research Annual conference; October 2009.

Feltner D, Hill C, Lenderking W, Williams VS, Morlock R. Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial. J Psychiatr Res. 2009 Oct;43(15):1224-30.

Hill C, McLeod LD. Advanced psychometric methods for PRO development - Item response theory. Presented at the 16th Annual Conference of the International Society for Quality of Life Research; October 2009.

Jackel J, Davis KL, Candrilli SD. Trends in rates of pediatric bipolar disorder-related hospitalizations and related resource use in the United States. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France.

Hong J, Reed C, Novick D, Haro JM, Aguado J. Clinical and economic consequences of medication nonadherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A355.

Rosen R, Shifren J, Monz B, Odom D, Russo P, Johannes C. The predictors of sexual distress in women with low sexual desire. Presented at the Annual Meeting of the International Society for the Study of Women's Sexual Health; September 1, 2009.